DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: OCREVUS (ocrelizumab)
       *****************************************************
       #Post#: 5195--------------------------------------------------
       Efficacy and safety of higher dose of ocrelizumab in RMS and
       PPMS [MUSETTE and GAVOTTE trials]
   DIR By: agate
       Date: June 3, 2026, 1:13 am
       ---------------------------------------------------------
       From The Lancet (May 30, 2026)--"Efficacy and safety of a
       bodyweight-adjusted higher dose of ocrelizumab in relapsing
       (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis:
       two multicentre, randomised, double-blind, parallel-group phase
       3b trials":
  HTML https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00147-9/fulltext
       *****************************************************
       Page 1 of 1